Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stake Trimmed by Man Group plc

Man Group plc reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 35.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 218,432 shares of the specialty pharmaceutical company's stock after selling 122,142 shares during the period. Man Group plc owned 0.68% of Collegium Pharmaceutical worth $6,258,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. MetLife Investment Management LLC raised its holdings in shares of Collegium Pharmaceutical by 8.5% in the fourth quarter. MetLife Investment Management LLC now owns 19,987 shares of the specialty pharmaceutical company's stock worth $573,000 after acquiring an additional 1,558 shares during the last quarter. Barclays PLC raised its stake in Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock valued at $2,899,000 after purchasing an additional 45,291 shares during the last quarter. Sanctuary Advisors LLC lifted its holdings in Collegium Pharmaceutical by 5.3% in the 4th quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company's stock valued at $542,000 after purchasing an additional 952 shares in the last quarter. Amundi lifted its holdings in Collegium Pharmaceutical by 188.3% in the 4th quarter. Amundi now owns 15,568 shares of the specialty pharmaceutical company's stock valued at $446,000 after purchasing an additional 10,168 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after purchasing an additional 316 shares during the last quarter.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares of the company's stock, valued at approximately $4,330,048.32. This trade represents a 20.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Colleen Tupper sold 977 shares of the business's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $29,310.00. Following the transaction, the chief financial officer now directly owns 164,269 shares of the company's stock, valued at approximately $4,928,070. This trade represents a 0.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,693 shares of company stock worth $2,334,994 over the last quarter. 2.51% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on COLL shares. Needham & Company LLC reissued a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Piper Sandler reissued a "neutral" rating and set a $37.00 price target (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. Wall Street Zen lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $43.80.

Collegium Pharmaceutical Trading Up 0.1%

Shares of NASDAQ:COLL traded up $0.04 during trading on Monday, reaching $28.86. 178,265 shares of the stock were exchanged, compared to its average volume of 427,975. The firm's 50-day moving average price is $28.11 and its 200 day moving average price is $29.67. The firm has a market cap of $927.33 million, a price-to-earnings ratio of 12.44 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). The business had revenue of $177.76 million during the quarter, compared to analysts' expectations of $174.96 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company's revenue for the quarter was up 22.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.45 EPS. On average, sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.